文献速递胃肠动力与功能性疾病食管胃疾病与幽门螺杆菌炎症性肠病

系统性硬化症胃肠道表现综述

Gastrointestinal Disorders in Scleroderma.
PubMed 文献 · Gastroenterology · 2026-04-15

本文综述系统性硬化症(SSc)的胃肠道表现,指出约90%患者食管受累,全消化道可因血管病变、免疫炎症和神经病变出现吞咽困难、胃轻瘫、假性梗阻、便秘及大便失禁等症状。动力障碍是核心特征,症状与病理生理常不平行,高质量治疗证据有限,管理多借鉴非SSc患者经验。

要点

  • SSc患者约90%食管受累,全消化道各段均可出现相应症状。
  • 动力障碍源于平滑肌萎缩和纤维化,可致小肠细菌过度生长、巨结肠等并发症。
  • 症状与胃肠道病理及功能损害相关性差,治疗证据有限,需个体化。

核心结论

  • SSc胃肠道受累常见且累及全消化道,动力障碍是核心特征,但症状与病理生理常不平行,高质量特异性治疗证据仍有限。

研究设计与样本

  • 本文为综述,系统阐述系统性硬化症胃肠道受累的病理机制、临床表现、诊断及治疗管理。

主要发现

  • 食管受累约见于90%的SSc患者,可表现为吞咽困难和胃食管反流病。
  • 胃受累可致胃轻瘫和胃窦血管扩张症;小肠受累可致毛细血管扩张、假性梗阻和小肠细菌过度生长。
  • 结肠受累可致便秘和结肠扩张;肛门括约肌变薄可致大便失禁。
  • 动力障碍由平滑肌萎缩和散在纤维化所致,可引发传输障碍、淤滞和管腔扩张,进而导致小肠细菌过度生长、巨结肠和肠囊样积气症等并发症。
  • 症状与胃肠道病理及功能损害相关性差,胃肠道表现与SSc疾病特征及自身抗体滴度的关联也不恒定。

关键数值与推荐

  • 食管受累约见于90%的SSc患者。
  • 高质量SSc特异性证据关于各种治疗对胃肠道表现的影响仍有限,多数胃肠道表现的管理推荐主要来自非SSc患者的经验。

临床怎么用

  • 消化内科医生应了解SSc胃肠道表现的临床特点和自然史,保持诊断警惕性,并结合SSc疾病过程制定个体化治疗策略。

局限性

  • 高质量SSc特异性证据有限,多数管理推荐基于非SSc患者经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Scleroderma, meaning "hard skin," refers to a heterogeneous group of disorders in which patients often experience skin thickening and fibrosis. In the systemic form of the disease, systemic sclerosis (SSc), internal organ involvement and vasculopathy are prominent features, with gastrointestinal (GI) involvement especially common and affecting the esophagus in approximately 90% of patients. Symptoms and clinical disorders that reflect GI involvement in the cardinal pathogenic features of scleroderma (ie, vasculopathy, immune-mediated inflammation, and neuropathy) emanate from every segment of the GI tract: dysphagia and gastroesophageal reflux disease from the esophagus; gastroparesis and gastric antral vascular ectasia from the stomach; telangiectasia, pseudo-obstruction, and small intestinal bacterial overgrowth from the small intestine; constipation and colonic dilatation; and fecal incontinence due to thinning of the anal sphincters. Impaired motility is a cardinal feature reflective of atrophy of smooth muscle and scattered areas of fibrosis throughout the GI tract and results in impaired transit, stasis, and luminal dilation leading to complications such as small intestinal bacterial overgrowth, megacolon, and pneumatosis cystoides intestinalis. Symptoms often correlate poorly with the underlying GI pathology and functional impairment in SSc, and associations between GI manifestations, SSc disease features, and autoantibody titers are variable. High-quality SSc-specific evidence regarding the impact of various therapies on GI manifestations remains limited, and management recommendations for most GI manifestations are largely derived from experience in non-SSc patients. In caring for the patient with SSc with GI problems, a gastroenterologist should be aware of the particularities of clinical presentation and natural history of GI disease in this patient population, maintain diagnostic vigilance, and tailor their therapeutic approach mindful of the SSc disease process.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Quigley EMM, McMahan ZH, Kulkarni S, et al. Gastrointestinal Disorders in Scleroderma. Gastroenterology. 2026. PMID: 41997504. doi:10.1053/j.gastro.2026.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。